{"id":"live-attenuated-h1n1-influenza-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL6068369","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains temperature-sensitive, attenuated H1N1 influenza virus that replicates in the cooler upper respiratory tract but not in the warmer lower respiratory tract, triggering both humoral and cellular immune responses. This approach induces mucosal and systemic immunity to prevent infection with wild-type H1N1 influenza virus. The attenuated virus is designed to be non-pathogenic while maintaining immunogenicity.","oneSentence":"A live attenuated influenza vaccine that contains weakened H1N1 virus strains to stimulate immune response without causing disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:35.646Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of H1N1 influenza infection in eligible populations"}]},"trialDetails":[{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT05223179","phase":"PHASE1","title":"Intramuscular CodaVax-H1N1 in Healthy Adults","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2022-04-11","conditions":"Influenza, Human","enrollment":69},{"nctId":"NCT06280144","phase":"PHASE4","title":"Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-09-22","conditions":"Influenza Prevention","enrollment":6080},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT04146623","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2019-05-07","conditions":"Influenza","enrollment":33},{"nctId":"NCT03926416","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2017-02-21","conditions":"Influenza","enrollment":125},{"nctId":"NCT02143882","phase":"PHASE4","title":"A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).","status":"COMPLETED","sponsor":"Public Health England","startDate":"2014-09","conditions":"Live Attenuated Influenza Vaccine","enrollment":300},{"nctId":"NCT02950688","phase":"PHASE1","title":"Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza, Human","enrollment":""},{"nctId":"NCT02964065","phase":"PHASE3","title":"A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2016-11","conditions":"Influenza","enrollment":9000},{"nctId":"NCT00344305","phase":"PHASE2","title":"A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-05-01","conditions":"Healthy","enrollment":200},{"nctId":"NCT01246999","phase":"PHASE4","title":"Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-10","conditions":"Influenza","enrollment":34},{"nctId":"NCT01055184","phase":"PHASE1, PHASE2","title":"Effects of Age on Response to the 2009 H1N1 Virus Vaccine","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-03","conditions":"2009 H1N1 Influenza Virus","enrollment":34},{"nctId":"NCT01023776","phase":"PHASE4","title":"Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2009-11","conditions":"Influenza","enrollment":20},{"nctId":"NCT01097941","phase":"PHASE4","title":"Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2010-03","conditions":"2009 H1N1 Influenza","enrollment":""},{"nctId":"NCT01797029","phase":"PHASE3","title":"A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh","status":"COMPLETED","sponsor":"PATH","startDate":"2013-02","conditions":"Influenza","enrollment":1761},{"nctId":"NCT01854632","phase":"PHASE3","title":"Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal","status":"COMPLETED","sponsor":"PATH","startDate":"2013-05","conditions":"Influenza","enrollment":1761},{"nctId":"NCT01625689","phase":"PHASE2","title":"Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine","status":"COMPLETED","sponsor":"PATH Vaccine Solutions","startDate":"2012-06","conditions":"Influenza","enrollment":309},{"nctId":"NCT01369862","phase":"PHASE1, PHASE2","title":"Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2011-01","conditions":"Influenza, Human","enrollment":80},{"nctId":"NCT01666262","phase":"PHASE1, PHASE2","title":"Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2009-09","conditions":"Healthy","enrollment":363},{"nctId":"NCT00192413","phase":"PHASE3","title":"Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-03","conditions":"Influenza","enrollment":3009},{"nctId":"NCT00192309","phase":"PHASE2","title":"Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2001-09","conditions":"Influenza","enrollment":31},{"nctId":"NCT00224783","phase":"PHASE1","title":"Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2002-08","conditions":"Healthy Japanese Male Adults","enrollment":45},{"nctId":"NCT01091246","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-03","conditions":"Healthy or Stable Chronic Illness","enrollment":2312},{"nctId":"NCT00945893","phase":"PHASE4","title":"A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Healthy","enrollment":300},{"nctId":"NCT00981513","phase":"PHASE4","title":"Direct and Indirect Benefits of Influenza Vaccination in Schools and Households","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2009-09","conditions":"Influenza Virus Infection, Influenza-like Illness, Acute Respiratory Infection","enrollment":6300},{"nctId":"NCT00946101","phase":"PHASE4","title":"A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Influenza","enrollment":326},{"nctId":"NCT01078701","phase":"PHASE2","title":"Dose Finding Study of Single Dose GHB11L1 in Healthy Adults","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2009-12","conditions":"Influenza, Human","enrollment":49},{"nctId":"NCT00724997","phase":"PHASE1","title":"Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2007-03","conditions":"Seasonal Human Influenza","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal"],"phase":"marketed","status":"active","brandName":"Live Attenuated H1N1 Influenza Vaccine","genericName":"Live Attenuated H1N1 Influenza Vaccine","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Biologic","firstApprovalDate":"","aiSummary":"A live attenuated influenza vaccine that contains weakened H1N1 virus strains to stimulate immune response without causing disease. Used for Prevention of H1N1 influenza infection in eligible populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}